{
    "nct_id": "NCT06031441",
    "official_title": "A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Life expectancy >=3 months, in the investigator's judgment\n* Adequate hematologic and end-organ function\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care\n* Measurable disease per RECIST v1.1\n* Tumor specimen availability, for certain cohorts\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to C1D1, with certain exceptions\n* Active hepatitis B or C\n* Active tuberculosis\n* Positive test for HIV infection\n* Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease\n* Prior allogeneic stem cell or organ transplantation\n* Uncontrolled tumor-related pain\n* Significant cardiovascular disease\n\nOther protocol-defined inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}